The present invention relates to a semi live respiratory syncytial virus (RSV) vaccine which comprises a genome replication deficient Sendai virus (SeV) vector expressing a chimeric RSV/SeV F protein. Furthermore the present invention relates to a method for the production of the genome replication deficient SeV vector of the present invention and the use thereof in the treatment of RSV infections and RSV infection related diseases.
